Two physicians, one a biotech entrepreneur, the other who discovered the first tumor biomarker, have teamed to bring an improved diagnostic test to a marketplace where an often chronic disease, breast cancer, unlike diabetes, has no blood test to measure progress or drug resistance. Having made BC progress, the company looks to a second test to achieve similar benefit in managing lung and kidney cancer.